Sleep apnea biotech hits market with $192M raise

Apnimed priced its IPO at $16 per share, raising $192 million for its clinical-stage pipeline targeting obstructive sleep apnea with a pill-based alternative to CPAP therapy.

Apnimed signals potential upsize to $160M IPO

Sleep apnea biotech Apnimed filed an updated prospectus as it prepares to price its $160 million IPO, signaling a potential upsize ahead of its public debut.

Apnimed amended its S-1 registration statement.

Sleep apnea drugmaker Apnimed is locked and loaded for its $150 million Nasdaq debut, pricing the offering at $14 to $16 per share as it brings a pill-based alternative to the CPAP machine market.

Sleep apnea biotech Apnimed files to go public on Nasdaq, banking on its oral drug candidate to displace CPAP machines as the market's standard treatment.